Mesothelioma vs Lung Cancer: 7 Key Differences in Diagnosis, Causes, and Treatment

Mesothelioma and lung cancer are two biologically distinct diseases that are frequently confused — by patients, families, and sometimes even clinicians. The first develops in the mesothelial lining surrounding the lungs [1], while the second grows inside the lung tissue itself [2]. This distinction matters enormously: it determines treatment approach, prognosis, and access to compensation programs. Studies in the Journal of Thoracic Oncology indicate that 10-25% of cases involving mesothelial tumors are initially misdiagnosed, often as a pulmonary malignancy [3].

What are the key facts comparing these two diseases?

• Cell Origin: Mesothelial tumors grow in the lining cells; pulmonary tumors grow in lung parenchyma (tissue)
• Annual U.S. Cases: ~3,000 mesothelial cancer vs. ~238,000 pulmonary cancer diagnoses per year [9]
• Asbestos Connection: Mesothelial cancer is caused almost exclusively by asbestos; asbestos causes ~4,500 lung cancer cases annually [12]
• Misdiagnosis Rate: 10-25% of mesothelial cancer cases are initially misdiagnosed [8]
• Median Survival (Mesothelial): 12-21 months with treatment [5]
• 5-Year Survival (Mesothelial): Approximately 12% [5]
• 5-Year Survival (Lung Cancer NSCLC): Approximately 28% [5]
• Diagnostic Test: Immunohistochemistry (IHC) panel distinguishes the two diseases
• Trust Fund Access: Both asbestos-caused diseases qualify for trust fund compensation
• Treatment Difference: Different surgical approaches, chemotherapy regimens, and clinical trials

Where does each disease originate in the body?

The most fundamental difference between these two cancers is where each begins at the cellular level. Mesothelioma develops in the mesothelium — a thin membrane of specialized cells that lines the chest cavity (pleura), abdominal cavity (peritoneum), and the sac around the heart (pericardium) [1]. Approximately 80% of cases are pleural, developing in the lining around the lungs rather than in the lungs themselves [6].

Lung cancer, by contrast, originates inside the lung tissue — in the cells lining the airways (bronchi), smaller air passages (bronchioles), or tiny air sacs (alveoli) [2]. The two main types are non-small cell lung cancer (NSCLC), which accounts for about 85% of cases, and small cell lung cancer (SCLC), which accounts for about 15% [11].

"First and foremost, we make sure the family understands exactly what the diagnosis means. The difference between these two diseases isn't just academic — it determines every treatment decision, every clinical trial option, and every legal right available to them. A correct diagnosis is the foundation everything else builds on."

— David Foster, Executive Director of Client Services, Danziger & De Llano

What causes each disease?

Mesothelioma has one dominant cause: asbestos exposure. The National Cancer Institute estimates that 70-80% of cases have a documented history of asbestos exposure, and most remaining cases likely involve unrecognized or forgotten exposure [1]. Non-asbestos causes are rare and include erionite fiber exposure and certain radiation treatments [7].

Lung cancer has multiple known causes. Cigarette smoking is responsible for approximately 80-90% of all lung cancer deaths [9]. Other causes include radon gas exposure (the second leading cause), air pollution, occupational carcinogens, and genetic factors [2]. However, asbestos exposure is also a significant cause — the EPA estimates approximately 4,500 asbestos-related lung cancer cases are diagnosed annually in the United States, distinct from the roughly 3,000 mesothelial cancer cases [12].

Does smoking affect these two diseases differently?

Smoking does not increase the risk of mesothelial tumors — this is a common misconception [1]. However, smoking dramatically increases the risk of asbestos-related lung cancer. A person exposed to asbestos who also smokes has a 50 to 90 times greater lung cancer risk compared to someone who neither smokes nor has asbestos exposure [7]. This synergistic effect makes the distinction critically important for asbestos-exposed workers who smoke.

Risk Factor	Mesothelioma	Lung Cancer
Asbestos exposure	Primary cause (70-80%+)	Significant cause (~4,500/year)
Smoking	No increased risk	Primary cause (80-90%)
Asbestos + smoking combined	No synergistic effect	50-90x increased risk
Radon gas	Not a factor	2nd leading cause
Latency period	20-50 years	10-30 years (asbestos-related)

How do the symptoms differ?

Symptom overlap is one of the primary reasons mesothelial cancer is misdiagnosed as a pulmonary malignancy [8]. Both diseases can cause shortness of breath, chest pain, fatigue, and weight loss. However, the pattern and character of symptoms differ in ways that help distinguish the two.

Symptoms more common in mesothelial cancer

• Chest wall pain: Localized, persistent pain in the chest wall from pleural thickening [1]
• Pleural effusion: Fluid buildup between the lung and chest wall, often the first detectable sign [1]
• Shortness of breath: Progressive, caused by fluid accumulation and pleural restriction
• Abdominal swelling: In the peritoneal form, fluid and tumor growth cause abdominal distension

Symptoms more common in lung cancer

• Persistent cough: Chronic cough that worsens over time, often the earliest symptom [2]
• Coughing blood (hemoptysis): More common in lung cancer because the tumor is inside the airways
• Visible lung mass: Lung cancer typically appears as a distinct mass on imaging
• Hoarseness: Tumor pressing on the recurrent laryngeal nerve [2]

Recognizing these symptoms early is critical for timely diagnosis. Any person with a history of asbestos exposure who develops chest pain, unexplained shortness of breath, or pleural effusion should specifically mention their exposure history to their physician and request evaluation for mesothelial disease.

"I always tell families to make sure the doctor knows about any asbestos exposure in the patient's history. That single piece of information changes the entire diagnostic workup. Without it, this disease can easily be mistaken for more common conditions, and that delay costs precious time."

— David Foster, Executive Director of Client Services, Danziger & De Llano

How does the diagnostic process differ?

Definitive diagnosis of both diseases requires tissue biopsy and pathological examination [3]. However, distinguishing mesothelial tumors from lung adenocarcinoma requires specialized immunohistochemistry (IHC) testing [4]. Standard pathology without IHC may not differentiate the two conditions, contributing to the 10-25% misdiagnosis rate [8].

Key diagnostic markers

Marker	Mesothelioma	Lung Adenocarcinoma
Calretinin	Positive (present)	Negative (absent)
WT-1	Positive	Negative
D2-40 (Podoplanin)	Positive	Negative
TTF-1	Negative	Positive
Napsin A	Negative	Positive
CEA	Usually negative	Usually positive

The IHC panel provides a molecular fingerprint that clearly identifies whether cancer cells are mesothelial or epithelial in origin [4]. Understanding your diagnosis requires confirming that proper IHC testing was performed. If the initial biopsy report does not include these markers, patients should request additional testing or seek a second opinion at a specialized treatment center.

How do treatment approaches differ?

Treatment for these two cancers follows different surgical, chemotherapy, and immunotherapy pathways. Using the wrong approach — which can happen with misdiagnosis — reduces treatment effectiveness and worsens outcomes.

Mesothelial cancer treatment

• Surgery: Pleurectomy/decortication (P/D) removes the pleural lining, or extrapleural pneumonectomy (EPP) removes the lung plus lining. These are specialized procedures performed at select centers [10].
• Chemotherapy: Standard first-line is pemetrexed plus cisplatin or carboplatin. This combination was specifically developed and approved for this disease [10].
• Immunotherapy: Nivolumab plus ipilimumab (Opdivo + Yervoy) is now approved as first-line treatment for unresectable pleural mesothelioma [10].
• Clinical trials: Disease-specific trials test novel approaches including targeted therapies and combination immunotherapy.

Lung cancer treatment

• Surgery: Lobectomy (removal of a lung lobe), wedge resection, or pneumonectomy. Different surgical approach than mesothelial cancer surgery [2].
• Chemotherapy: Platinum-based doublets (different regimens than for mesothelial tumors). Targeted therapies for specific mutations (EGFR, ALK, ROS1).
• Immunotherapy: Pembrolizumab (Keytruda) and other checkpoint inhibitors, often combined with chemotherapy [9].
• Targeted therapy: Mutation-specific drugs (erlotinib, osimertinib, crizotinib) — not applicable to mesothelial cancer.

"Treatment centers that specialize in this disease have surgeons who perform these procedures regularly. That surgical volume matters — studies consistently show better outcomes at high-volume centers. We help connect every patient with the right specialists for their specific diagnosis."

— David Foster, Executive Director of Client Services, Danziger & De Llano

How does prognosis compare between the two diseases?

Both diseases are serious diagnoses, but survival statistics differ. According to the NCI SEER database, pleural mesothelioma has an overall five-year survival rate of approximately 12% [5]. Lung cancer survival varies widely by type and stage — non-small cell has a five-year survival rate of about 28%, while small cell is approximately 7% [5].

Factors that improve prognosis for both diseases include earlier stage at diagnosis, younger age, better overall health, access to specialized treatment, and eligibility for multimodal therapy [9]. For mesothelial cancer specifically, treatment at a specialized center with experienced surgeons correlates with significantly better outcomes [10]. The survival statistics continue to improve as new treatments including immunotherapy become standard of care.

What are the legal and compensation differences?

Both mesothelial cancer and asbestos-related lung cancer qualify for legal compensation, but the pathways and documentation requirements differ.

Mesothelial cancer legal options

This disease is caused almost exclusively by asbestos, making causation relatively straightforward to establish in legal proceedings [1]. Patients can access over $30 billion in asbestos trust funds, file personal injury lawsuits, and pursue VA benefits (for veterans). A mesothelioma diagnosis alone establishes the asbestos-disease link.

Asbestos-related lung cancer legal options

Lung cancer caused by asbestos also qualifies for trust fund compensation and legal claims, but proving the asbestos connection requires additional documentation since lung cancer has multiple possible causes [12]. Medical evidence establishing the asbestos link (exposure history, presence of asbestosis, pleural plaques, or pathological markers) is needed. An experienced asbestos attorney can help establish the asbestos connection for lung cancer cases.

"My father died of asbestos lung cancer in 1999. I know firsthand how important the correct diagnosis is — not just for treatment, but for ensuring families have access to every compensation program they're entitled to. Whether it's mesothelial cancer or asbestos-related lung cancer, there are legal options available."

— David Foster, Executive Director of Client Services, Danziger & De Llano

Frequently asked questions

Is mesothelioma the same as lung cancer?

No. These are two distinct diseases [1]. Mesothelioma originates in the mesothelial lining surrounding the lungs, abdomen, or heart. Lung cancer originates inside the lung tissue itself [2]. They differ in cell type, causes, treatment approaches, and prognosis. Both can be caused by asbestos exposure, and mesothelial tumors are sometimes initially misdiagnosed as pulmonary malignancies.

Can asbestos cause both diseases?

Yes. Asbestos exposure can cause both conditions through different mechanisms [7]. Mesothelial tumors develop when inhaled fibers become embedded in the mesothelial lining. Asbestos-related lung cancer develops when fibers penetrate deep into lung tissue. Approximately 4,500 cases of asbestos-related lung cancer are diagnosed annually compared to about 3,000 mesothelial cancer cases [12].

How is the diagnostic process different?

Both require tissue biopsy, but immunohistochemistry (IHC) testing distinguishes them [4]. Mesothelial tumors are identified by markers like calretinin, WT-1, and D2-40. Lung cancer is identified by TTF-1 and Napsin A. On CT scans, the mesothelial form appears as pleural thickening while pulmonary cancer appears as a lung mass. The medical terminology on pathology reports can be complex — patients should ask their oncologist to explain results clearly.

Why does the specific diagnosis matter?

Correct diagnosis determines treatment, prognosis, and legal options. These two diseases require different surgical techniques, different chemotherapy regimens, and qualify for different compensation programs. Misdiagnosis can lead to less effective treatment and missed financial resources.

How do survival rates compare?

Mesothelioma has a five-year survival rate of approximately 12% and median survival of 12-21 months [5]. Non-small cell lung cancer has a five-year survival rate of about 28% [5]. The small cell form has a five-year survival rate of approximately 7% [5]. Prognosis for both diseases improves with early detection and specialized treatment.

Can mesothelial cancer be misdiagnosed as lung cancer?

Yes. Studies suggest 10-25% of cases are initially misdiagnosed [3][8]. This typically occurs when initial biopsies are too small for proper IHC testing, or when pathologists without specialized expertise interpret the samples. Seeking a second opinion from an asbestos disease specialist is strongly recommended.

Do these two diseases have different symptoms?

While symptoms overlap, mesothelial cancer more commonly presents with chest wall pain and pleural effusion. Lung cancer more commonly presents with persistent cough and hemoptysis (coughing blood). Both cause shortness of breath, weight loss, and fatigue. The symptom overlap is one reason misdiagnosis occurs.

What should patients with an asbestos-related cancer diagnosis do?

Whether the diagnosis is mesothelioma or asbestos-related lung cancer, patients and families should take three immediate steps: confirm the diagnosis with proper immunohistochemistry testing (especially if mesothelial disease is suspected), seek treatment at a specialized treatment center, and consult an experienced asbestos attorney to evaluate all compensation options.

Our team at Danziger & De Llano has helped thousands of families navigate both mesothelial and asbestos-related lung cancer diagnoses. We provide free case evaluations and work on a contingency fee basis — there is no cost unless we recover compensation.

Related resources

• Asbestos Trust Funds: $30+ Billion Compensation Guide
• Veterans Benefits and VA Disability for Asbestos Disease
• Find Asbestos Disease Lawyers by State
• Free Case Assessment

Last updated: February 5, 2026

References

1. [1] National Cancer Institute. "Mesothelioma: Clinical Features and Diagnosis." 2025. cancer.gov
2. [2] National Cancer Institute. "Lung Cancer: Treatment and Prevention." 2025. cancer.gov
3. [3] Journal of Thoracic Oncology. "Differential Diagnosis of Pleural Mesothelioma and Lung Adenocarcinoma." 2024. PubMed
4. [4] Archives of Pathology and Laboratory Medicine. "Immunohistochemistry in Mesothelioma Diagnosis Guidelines." 2024. PubMed
5. [5] National Cancer Institute SEER Program. "SEER Cancer Statistics Review: Mesothelioma." 2025. seer.cancer.gov
6. [6] Annals of Oncology. "Asbestos-Related Lung Cancer vs Mesothelioma: Epidemiological Differences." 2023. PubMed
7. [7] Agency for Toxic Substances and Disease Registry. "ATSDR Toxicological Profile: Asbestos and Cancer Risk." 2024. atsdr.cdc.gov
8. [8] Lung Cancer. "Mesothelioma Misdiagnosis Rate Analysis." 2024. PubMed
9. [9] American Cancer Society. "ACS Cancer Statistics 2025." 2025. cancer.org
10. [10] National Comprehensive Cancer Network. "Mesothelioma Surgical Treatment Guidelines." 2025. nccn.org
11. [11] World Health Organization / IARC. "WHO Classification of Tumours: Thoracic Tumours." 2024. publications.iarc.fr
12. [12] U.S. Environmental Protection Agency. "Asbestos Exposure and Cancer Risk Assessment." 2024. epa.gov